The cardiovascular effects of histamine in laboratory animals.
Explore the source record for details and available documents.
Biomedical subjects
Publications and source records attributed to M E Parsons.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
A number of methods which might improve the detection of carriers of Duchenne muscular dystrophy, based on the estimation of serum creatine kinase (CK), have been tried in an attempt to improve the 70% detection rate obtained with random samples. One series of experiments involved controlled exercise on a bicycle ergometer, the second series was based on sampling of muscle venous blood after controlled ischaemic exercise, and a third series of experiments was carried out to see whether the rate of enzyme inactivation was different in carriers of Duchenne dystrophy compared with controls. These methods were not found to improve the carrier detection rate based upon serum CK estimation.
1. Isoelectric focusing of human liver alkaline phosphatase in a sucrose density gradient with LKB Ampholine as carrier ampholytes is described. 2. Problems due to the chelating properties of the ampholytes and the pH gradient were examined. 3. A reactivation procedure to counter these effects was devised that can probably be used for other alkaline phosphatases. 4. The isoelectric point of human liver alkaline phosphatase was found to be pH3.9.
Explore the source record for details and available documents.
SK&F 93319 (icotidine), 2-[4-(3-methoxypyrid-2-yl)butylamino]-5-[(6-methylpyrid-3-yl )-methyl]- pyrimidin-4-one trihydrochloride, has been identified as a novel agent which combines into one molecule the ability to antagonize the actions of histamine at H1 and H2 receptors across a similar concentration or dose range. The degree of antagonism of vascular responses to histamine exceeds that possible with either an H1- or H2-receptor histamine antagonist alone. SK&F 93319 may have therapeutic utility in conditions requiring simultaneous antagonism of histamine at H1 and H2 receptors.
Explore the source record for details and available documents.